NeoGenomics, Inc. (NEO)
| Market Cap | 2.16B +84.1% |
| Revenue (ttm) | 766.30M +11.2% |
| Net Income | -51.88M |
| EPS | -0.40 |
| Shares Out | 128.48M |
| PE Ratio | n/a |
| Forward PE | 61.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 970,833 |
| Open | 16.30 |
| Previous Close | 16.20 |
| Day's Range | 15.98 - 16.98 |
| 52-Week Range | 7.07 - 20.15 |
| Beta | 1.78 |
| Analysts | Buy |
| Price Target | 21.55 (+27.97%) |
| Est. Earnings | Oct 27, 2026 |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and ge... [Read more]
Financial Performance
In 2025, NeoGenomics's revenue was $727.33 million, an increase of 10.11% compared to the previous year's $660.57 million. Losses were -$108.03 million, 37.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NEO stock is "Buy." The 12-month stock price target is $21.55, which is an increase of 27.97% from the latest price.
News
NeoGenomics price target raised to $20 from $16 at BofA
BofA raised the firm’s price target on NeoGenomics (NEO) to $20 from $16 and keeps a Neutral rating on the shares. While Neogenomics’ disclosure yesterday of a CEO transition “came…
NeoGenomics price target raised to $20 from $16 at StoneX
StoneX analyst Bruce Jackson raised the firm’s price target on NeoGenomics (NEO) to $20 from $16 and keeps a Buy rating on the shares following the company’s “positive” Q3 preannouncement…
NeoGenomics upgraded to Buy from Neutral at BTIG
BTIG upgraded NeoGenomics (NEO) to Buy from Neutral with a $28 price target The shares are up 62% year-to-date but trade at just 3-times the 2027 consensus revenue estimate, the…
NeoGenomics down 2% at $18.73 after Q3 pre-announcement, CEO transition
16:44 EDT NeoGenomics (NEO) down 2% at $18.73 after Q3 pre-announcement, CEO transition
NeoGenomics sees Q3 revenue of about $209M, consensus $205.9M
The company states: “Although NeoGenomics (NEO) has not finalized its financial results as of and for the quarter ended September 30, 2026, NeoGenomics expects to report third quarter total revenue…
NeoGenomics names Warren Stone as new CEO effective 2027
The company states: “NeoGenomics (NEO) announced that as part of a planned succession, its Board of Directors has appointed Warren Stone, current President and Chief Operating Officer (COO), as Chief…
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of directors succession plan.
NeoGenomics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Focused on community oncology, the company leverages a broad portfolio and workflow solutions to drive growth, with NGS revenue expanding at 26% and new products like PanTracer and RaDaR ST strengthening its competitive edge. Strategic investments in R&D, sales, and IT infrastructure support continued margin and cash flow improvements.
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.
NeoGenomics receives Medicare coverage for RaDaR ST MRD assay
NeoGenomics (NEO) announced that its RaDaR ST molecular residual disease assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program t...
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.
NeoGenomics price target raised to $19 from $17 at Craig-Hallum
Craig-Hallum raised the firm’s price target on NeoGenomics (NEO) to $19 from $17 and keeps a Buy rating on the shares. The firm notes NeoGenomics reported a modest revenue beat…
NeoGenomics price target raised to $19 from $15 at Needham
Needham raised the firm’s price target on NeoGenomics (NEO) to $19 from $15 and keeps a Buy rating on the shares after its Q2 earnings beat and guidance raise. Organic…
NeoGenomics Earnings Call Transcript: Q2 2026
Q2 revenue rose 11% year-over-year to $201.7 million, led by 14% clinical growth and 26% NGS growth. Gross margin expanded 260 bps, and adjusted EBITDA grew 36%. Full-year guidance was raised, with continued focus on high-value testing, margin expansion, and commercial execution.
NeoGenomics Earnings release: Q2 2026
NeoGenomics released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
NeoGenomics Quarterly report: Q2 2026
NeoGenomics has published its Q2 2026 quarterly earnings report on July 28, 2026.
NeoGenomics Slides: Q2 2026
NeoGenomics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
NeoGenomics reports Q2 EPS 5c, consensus 3c
Reports Q2 revenue $201.7M, consensus $197.0M. “Our second quarter results reflect the consistent operating and financial performance investors expect from this team,” said Tony Zook, Chief Executive ...
NeoGenomics raises FY26 revenue view from $797M-$803M to $802M-$806M
Consensus $800.4M. Raises FY26 adjusted EBITDA view to $56M-$58M from $55M-$57M.
NeoGenomics Reports Second Quarter 2026 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.
NeoGenomics price target raised to $16 from $11 at Benchmark
Benchmark raised the firm’s price target on NeoGenomics (NEO) to $16 from $11 and keeps a Buy rating on the shares ahead of the company’s Q2 results due on July…
NeoGenomics announces settlement of voluntary disclosure to OIG-HHS
NeoGenomics (NEO) has finalized a civil settlement with the Department of Justice, or DOJ, on behalf of the Office of Inspector General of the U.S. Department of Health and Human…
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has fina...
NeoGenomics price target raised to $19 from $14 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on NeoGenomics (NEO) to $19 from $14 and keeps a Buy rating on the shares. The firm adjusted targets in…
NeoGenomics price target raised to $16 from $11 at BofA
BofA raised the firm’s price target on NeoGenomics (NEO) to $16 from $11 and keeps a Neutral rating on the shares as part of the firm’s Q2 earnings preview for…